{"protocolSection": {"identificationModule": {"nctId": "NCT01681576", "orgStudyIdInfo": {"id": "CLCZ696A2222"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension", "officialTitle": "A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension"}, "statusModule": {"statusVerifiedDate": "2015-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-08"}, "primaryCompletionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-08-30", "studyFirstSubmitQcDate": "2012-09-05", "studyFirstPostDateStruct": {"date": "2012-09-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-10", "resultsFirstSubmitQcDate": "2015-09-08", "resultsFirstPostDateStruct": {"date": "2015-10-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-10-12", "lastUpdatePostDateStruct": {"date": "2015-11-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients."}, "conditionsModule": {"conditions": ["Salt-sensitive Hypertension"], "keywords": ["hypertension, salt sensitivity, valsartan, LCZ696"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 72, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696 followed by Valsartan", "type": "EXPERIMENTAL", "description": "Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks", "interventionNames": ["Drug: Valsartan", "Drug: LCZ696"]}, {"label": "Valsartan followed by LCZ696", "type": "EXPERIMENTAL", "description": "Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks", "interventionNames": ["Drug: Valsartan", "Drug: LCZ696"]}], "interventions": [{"type": "DRUG", "name": "Valsartan", "description": "Valsartan 320mg tablet once daily", "armGroupLabels": ["LCZ696 followed by Valsartan", "Valsartan followed by LCZ696"]}, {"type": "DRUG", "name": "LCZ696", "description": "LCZ696 400mg tablet once daily", "armGroupLabels": ["LCZ696 followed by Valsartan", "Valsartan followed by LCZ696"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cumulative Sodium Excretion (Natriuresis) at Day 1", "description": "Urine will be collected in fractions of 6 to 24 hours post-dose. From each fraction, a sample will be drawn for analysis of sodium Day 1", "timeFrame": "0-6 and 0-24 hours on Day 1"}], "secondaryOutcomes": [{"measure": "Cumulative Sodium Excretion (Natriuresis) at Day 28", "description": "Urine will be collected in fractions of 6 to 24 hours post-dose. From each fraction, a sample will be drawn for analysis of sodium Day 28", "timeFrame": "0-6 and 0-24 hours on Day 28"}, {"measure": "Urine Volume (Diuresis) Over Time", "description": "Urine will be collected and volume measured in fractions of 0 to 6 hours and 0 to 24 hours Day-1, Day 1 and Day 28", "timeFrame": "Day -1, Day 1 & Day 28"}, {"measure": "Seated Office Blood Pressure (BP) (Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)) Over Time", "description": "Seated Office BP (systolic blood pressure (SBP) and diastolic blood pressure (DBP))measurements will be performed at trough(immediately prior to dosing at the clinic). Arterial BP readings will be made with an automated BP device.", "timeFrame": "Day-1, Day 14 and Day 28"}, {"measure": "Mean Sitting Pulse Pressure (PP) Over Time", "description": "Sitting mean pulse pressure rate was calculated between ambulatory SBP and DBP measurements", "timeFrame": "Day-1, Day 14 and Day 28"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* Written informed consent must be obtained before any study assessment is performed.\n* Males and females of non-childbearing potential and of legal age (at least 18 years or older as defined by local law).\n* Asian patients with mild to moderate essential hypertension, untreated or currently taking antihypertensive therapy with up to two drugs.\n\nKey Exclusion Criteria:\n\n* Women of child-bearing potential.\n* History of angioedema, drug-related or otherwise\n* History of hypersensitivity to LCZ696, valsartan, or drugs of similar chemical classes.\n* Severe hypertension (grade 3 of WHO classification; msDBP \u2265100 mmHg and/or msSBP \u2265 180 mmHg) at screening or at the end of the washout period.\n* History or evidence of a secondary form of hypertension,\n* Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke.\n* History of myocardial infarction, coronary bypass surgery or percutaneous coronary intervention (PCI) during 12 month prior to screening.\n* Current or history of hypertensive retinopathy.\n* Previous or current diagnosis of heart failure (NYHA Class II-IV).\n* Clinically significant valvular heart disease at screening.\n\nOther protocol defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Novartis Investigative Site", "city": "Cypress", "state": "California", "zip": "90630", "country": "United States", "geoPoint": {"lat": 33.81696, "lon": -118.03729}}, {"facility": "Novartis Investigative Site", "city": "Glendale", "state": "California", "zip": "91206", "country": "United States", "geoPoint": {"lat": 34.14251, "lon": -118.25508}}, {"facility": "Novartis Investigative Site", "city": "Hong Kong", "state": "Shatin, NT", "country": "Hong Kong", "geoPoint": {"lat": 22.27832, "lon": 114.17469}}, {"facility": "Novartis Investigative Site", "city": "Bucheon", "state": "Gyeonggi-do", "zip": "424-717", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Novartis Investigative Site", "city": "Koyang-si", "state": "Gyeonggi-do", "zip": "410-773", "country": "Korea, Republic of"}, {"facility": "Novartis Investigative Site", "city": "Seoul", "state": "Korea", "zip": "110 744", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "zip": "120-752", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "zip": "152-703", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "119228", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "169609", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "state": "Taiwan, ROC", "zip": "112", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Novartis Investigative Site", "city": "Taichung", "zip": "40447", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "zip": "10002", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "zip": "114", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}]}, "referencesModule": {"references": [{"pmid": "27849566", "type": "DERIVED", "citation": "Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, Pal P, Yang F, Hirschhorn E, Prescott MF, Hinder M, Langenickel TH. Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. Hypertension. 2017 Jan;69(1):32-41. doi: 10.1161/HYPERTENSIONAHA.116.08484. Epub 2016 Nov 14."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Period 1: 4 weeks treatment with LCZ696 400mg QD or Valsartan 320mg, 1-2 weeks wash-out, followed by period 2, 4 weeks treatment with Valsartan 320mg QD or LCZ696 400mg QD", "groups": [{"id": "FG000", "title": "LCZ696 Followed by Valsartan", "description": "Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks"}, {"id": "FG001", "title": "Valsartan Followed by LCZ696", "description": "Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks"}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Period 2: Valsartan 320mg", "numSubjects": "34"}, {"groupId": "FG001", "comment": "Period 2: LCZ696 400mg", "numSubjects": "36"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "35"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "subject/guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Non-compliance with study treatment", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696 Followed by Valsartan", "description": "Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks"}, {"id": "BG001", "title": "Valsartan 320mg", "description": "Period 1: 4 weeks treatment with Valsartan 320mg QD, 1-2 weeks wash-out, followed by period 2, 4 weeks treatment with LCZ696 400mg QD"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "72"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.7", "spread": "12.5"}, {"groupId": "BG001", "value": "58.9", "spread": "7.5"}, {"groupId": "BG002", "value": "57.3", "spread": "10.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "46"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Cumulative Sodium Excretion (Natriuresis) at Day 1", "description": "Urine will be collected in fractions of 6 to 24 hours post-dose. From each fraction, a sample will be drawn for analysis of sodium Day 1", "populationDescription": "Pharmacodynamic PD analysis set: Patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol", "timeFrame": "0-6 and 0-24 hours on Day 1", "groups": [{"id": "OG000", "title": "LCZ696 - ALL", "description": "LCZ696 400mg QD"}, {"id": "OG001", "title": "Valsartan -ALL", "description": "Valsartan 320mg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "0-6h (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.26", "spread": "31.167"}, {"groupId": "OG001", "value": "37.13", "spread": "20.761"}]}]}, {"title": "0-24h (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "188.87", "spread": "74.458"}, {"groupId": "OG001", "value": "138.92", "spread": "58.905"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative Sodium Excretion (Natriuresis) at Day 28", "description": "Urine will be collected in fractions of 6 to 24 hours post-dose. From each fraction, a sample will be drawn for analysis of sodium Day 28", "populationDescription": "Pharmacodynamic PD analysis set: Patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol", "timeFrame": "0-6 and 0-24 hours on Day 28", "groups": [{"id": "OG000", "title": "LCZ696 - ALL", "description": "LCZ696 400mg"}, {"id": "OG001", "title": "Valsartan - ALL", "description": "Valsartan 320mg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "0-6h (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "39.30", "spread": "18.841"}, {"groupId": "OG001", "value": "44.57", "spread": "23.479"}]}]}, {"title": "0-24h (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "144.71", "spread": "51.094"}, {"groupId": "OG001", "value": "153.82", "spread": "62.449"}]}]}]}, {"type": "SECONDARY", "title": "Urine Volume (Diuresis) Over Time", "description": "Urine will be collected and volume measured in fractions of 0 to 6 hours and 0 to 24 hours Day-1, Day 1 and Day 28", "populationDescription": "Pharmacodynamic PD analysis set: Patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL", "timeFrame": "Day -1, Day 1 & Day 28", "groups": [{"id": "OG000", "title": "LCZ696 - ALL", "description": "LCZ696 400mg"}, {"id": "OG001", "title": "Valsartan - ALL", "description": "Valsartan 320mg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Day -1 0-6h (n=70,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "855.1", "spread": "450.28"}, {"groupId": "OG001", "value": "806.2", "spread": "462.20"}]}]}, {"title": "Day -1 0-24h (n=70,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2752.8", "spread": "722.53"}, {"groupId": "OG001", "value": "2756.2", "spread": "1010.86"}]}]}, {"title": "Day 1 0-6h (n=70,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1215.9", "spread": "475.57"}, {"groupId": "OG001", "value": "923.0", "spread": "443.65"}]}]}, {"title": "Day 1 0-24h (n=70,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3172.3", "spread": "957.70"}, {"groupId": "OG001", "value": "2813.8", "spread": "930.05"}]}]}, {"title": "Day 28 0-6h (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "948.8", "spread": "415.14"}, {"groupId": "OG001", "value": "1042.7", "spread": "530.15"}]}]}, {"title": "Day 28 0-24h (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2820.0", "spread": "847.81"}, {"groupId": "OG001", "value": "3000.2", "spread": "1139.75"}]}]}]}, {"type": "SECONDARY", "title": "Seated Office Blood Pressure (BP) (Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)) Over Time", "description": "Seated Office BP (systolic blood pressure (SBP) and diastolic blood pressure (DBP))measurements will be performed at trough(immediately prior to dosing at the clinic). Arterial BP readings will be made with an automated BP device.", "populationDescription": "Pharmacodynamic PD analysis set: Patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Day-1, Day 14 and Day 28", "groups": [{"id": "OG000", "title": "LCZ696 - ALL", "description": "LCZ696 400mg"}, {"id": "OG001", "title": "Valsartan - ALL", "description": "Valsartan 320mg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Day -1 Sitting SBP (n=70,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.20", "spread": "13.691"}, {"groupId": "OG001", "value": "137.85", "spread": "12.703"}]}]}, {"title": "Day 28 Sitting SBP (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "127.01", "spread": "12.723"}, {"groupId": "OG001", "value": "132.07", "spread": "15.195"}]}]}, {"title": "Day 14 Sitting DBP (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.43", "spread": "7.808"}, {"groupId": "OG001", "value": "80.57", "spread": "9.246"}]}]}, {"title": "Day 28 Sitting DBP (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.44", "spread": "7.840"}, {"groupId": "OG001", "value": "81.40", "spread": "9.276"}]}]}, {"title": "Day 14 Sitting SBP (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "126.88", "spread": "12.451"}, {"groupId": "OG001", "value": "129.23", "spread": "12.784"}]}]}, {"title": "Day -1 Sitting DBP (n=70,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "86.63", "spread": "8.955"}, {"groupId": "OG001", "value": "85.59", "spread": "9.299"}]}]}]}, {"type": "SECONDARY", "title": "Mean Sitting Pulse Pressure (PP) Over Time", "description": "Sitting mean pulse pressure rate was calculated between ambulatory SBP and DBP measurements", "populationDescription": "Pharmacodynamic PD analysis set: Patients with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Day-1, Day 14 and Day 28", "groups": [{"id": "OG000", "title": "LCZ696 - ALL", "description": "LCZ696 400mg"}, {"id": "OG001", "title": "Valsartan - ALL", "description": "Valsartan 320mg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Day -1 Sitting mean PP (n=70,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.91", "spread": "8.392"}, {"groupId": "OG001", "value": "64.92", "spread": "10.086"}]}]}, {"title": "Day 14 Sitting mean PP (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.91", "spread": "10.370"}, {"groupId": "OG001", "value": "69.61", "spread": "8.888"}]}]}, {"title": "Day 28 Sitting mean PP (n=69,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.21", "spread": "8.999"}, {"groupId": "OG001", "value": "63.63", "spread": "8.843"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "description": "Overall, 72 patients with salt-sensitive hypertension were randomized to one of the two crossover treatment arms. For the Safety Set: overall, 71 patients were exposed to at least one dose of LCZ696 400 mg and a total of 67 patients were exposed to at least one dose of valsartan 320 mg.", "eventGroups": [{"id": "EG000", "title": "LCZ696 400 mg QD", "description": "LCZ696 400 mg QD", "seriousNumAffected": 0, "seriousNumAtRisk": 71, "otherNumAffected": 15, "otherNumAtRisk": 71}, {"id": "EG001", "title": "Valsartan 320 mg QD", "description": "Valsartan 320 mg QD", "seriousNumAffected": 0, "seriousNumAtRisk": 67, "otherNumAffected": 15, "otherNumAtRisk": 67}], "otherEvents": [{"term": "DRY MOUTH", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 67}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 67}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 67}]}, {"term": "FLANK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 67}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 67}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 67}]}, {"term": "HAEMATURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 67}]}, {"term": "PYURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 67}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 67}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000006967", "term": "Hypersensitivity"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "asFound": "Sensitive", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}